glp 1 drugs and dementia GLP-1 failed to slow Alzheimer's in two big clinical trials GLP-1 Drugs Linked to Lower

N Engl J Med 377:839848 Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Furthermore, it is to determine whether the risk may differ by GLP-1RA type, trial duration, control type, and indication

Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al

4 , 5 Given their expanding use in populations with obesity, T2DM, and cardiovascular disease, a deeper understanding of their impact on BP is increasingly relevant

Accordingly, the pharmaceutical market for obesity drugs is growing at an unprecedented rate